SCTbio and Fortrea (FTRE) announced a strategic collaboration agreement between the two companies. This partnership aims to streamline development, accelerate timelines and bring advanced therapies to patients faster. This collaboration represents a forward-looking model for how CDMOs and CROs can collaborate to deliver synchronized solutions that help to de-risk programs, streamline planning, expedite study setup and optimize cost-efficiency across the entire development lifecycle. According to The American Society of Cell & Gene Therapy, there are more than 4,400 gene, cell and RNA therapies currently in development.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FTRE:
- Fortrea completes $75.7M senior notes tender offer
- Fortrea Holdings Completes Oversubscribed Debt Tender Offer
- Fortrea appoints Gallagher as General Counsel
- Starboard takes new stake in Bill Holdings, exits Pfizer position
- Cautious Outlook for Fortrea Holdings Inc. Amid 2026 Challenges and Potential 2027 Recovery